NCT01651364

A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: Baylor College of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effects of treatment with cabergoline, compared to treatment with placebo, on cocaine induced craving and subjective effects in cocaine-dependent human volunteers.

Detailed description

Secondary aims are to clarify the genetics of substance abuse, potentially leading to improved methods to diagnosis those at risk and to help develop better therapeutic interventions and to develop a new saliva-based test for the detection and measurement of drugs of abuse. As an additional aim, we will also collect blood samples for analyzing a number of genetic polymorphisms.

Conditions

• Cocaine Dependence
• Cocaine Abuse
• Cocaine Addiction
• Substance Abuse

Interventions

Type	Name	Description
DRUG	Placebo	Enrolled volunteers will be randomized on Day 8 to receive placebo (n=2) or study medication (n=8). Placebo serves only to maintain the blind and is not a comparator.
DRUG	Cabergoline	Enrolled volunteers that receive study medication (n=8) will receive cabergoline 0.25 mg twice weekly.

Timeline

• Start date: 2011-07-01
• Primary completion: 2011-10-01
• Completion: 2011-10-01
• First posted: 2012-07-27
• Last updated: 2012-07-27

Locations

1 site across 1 country: United States